Medicines

Tau Therapy Shows Continued Benefit at 2 Years in Alzheimer's

MedPage Today(MedPage Today) -- Diranersen, an investigational antisense oligonucleotide therapy that targets tau, continued to show benefits for 96 weeks, data from the open-label extension of the phase II CELIA trial suggested. At 2 years, diranersen continued...

More Medicines

Top Medicines stories

More Medicines stories

Latest Medicines headlines

  1. Study of 750,000 pregnancies reveals a surprising twist about Ozempic and WegovyScienceDaily
  2. Ozempic and Zepbound users face 6 rebound risks after stopping, doctor warnsFox News
  3. White House Yanks Pick for FDA ChiefMedPage Today
  4. STAT+: Pharmalittle: We’re reading about a Roche breast cancer pill, obesity drugs in children, and moreSTAT
  5. FDA Adds Another Player in ALK-Positive Lung CancerMedPage Today
  6. Laboratoires Pierre Fabre Announce FDA Fast Track Designation for Elticertinib in NSCLCDrugs.com
  7. FDA Grants Accelerated Approval to Nelkarmi (neladalkib) for Previously-Treated Advanced ALK-Positive Non-Small Cell Lung CancerDrugs.com

Our Advertisers